Burst Diagnostics develops a portable immunoassay device, CaDI, that delivers lab-quality antigen testing with high sensitivity and rapid results. This technology addresses the need for accurate and timely diagnostics in at-home and point-of-care settings, enhancing patient care and treatment efficiency.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current lab-based antigen tests require specialized equipment and trained personnel, limiting accessibility and delaying results, especially in point-of-care or at-home settings. This can hinder timely diagnosis and treatment, impacting patient outcomes and healthcare efficiency.
Solution
Burst Diagnostics offers CaDI, a portable immunoassay device designed to deliver lab-quality antigen testing with high sensitivity and rapid results. CaDI aims to empower users with simple, accurate diagnostics when and where they’re needed. The device provides rapid, cost-effective, and precise testing capabilities in a compact form factor. CaDI seeks to revolutionize diagnostics by providing unmatched efficiency without compromising on quality.
Target Audience
The primary target audience includes healthcare providers, point-of-care facilities, and individuals seeking rapid and accurate antigen testing in decentralized settings.
Features
- Portable immunoassay device for antigen testing
- Delivers lab-quality results with high sensitivity
- Provides rapid results for timely diagnosis
- Cost-effective testing capabilities
- Compact design for point-of-care and at-home use